T-Cell Project: Epidemiologic Component
Peripheral T-Cell LymphomaBackground: The T-Cell Project, sponsored by the International T-cell non-Hodgkin Lymphoma Study Group, is a consortium of institutions interested in achieving more detailed information on clinical and biological characteristics of T-cell lymphomas. The T-Cell Project serves as a repository for data on patients with peripheral T-cell lymphoma (PTCL) worldwide. Its overall goal is to improve T-cell subtype classifications and evaluate treatment strategies for each subtype. Objectives: -To implement a standardized epidemiologic questionnaire into the ongoing T-Cell Project to allow evaluation of various potential risk factors for PTLCs. Eligibility: -Untreated patients 18 years of age and older who were diagnosed with PTLC September 1, 2006, or later. Design: -Patients complete a questionnaire containing the following information: Demographic information Smoking history and alcohol use Personal history or cancer History of cancer among first-degree relatives Medical history History of transplants History of blood transfusions Medication use Occupational and residential history Pesticide treatment -The information collected is linked to clinical and pathologic information in the T-Cell Project database.
Gemcitabine in NK/T Cell Lymphoma
NK/T Cell LymphomaWe retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
T-cell LymphomaRadiation therapy, total skin electron therapy (TSET), achieves a high response rate and is an effective treatment for cutaneous T-cell lymphoma affecting the superficial region 1. One the most widely used TSET techniques consists of six dual fields initially developed at Stanford University 2. Dosimetrically, TSET at energies of about 3-7 MeV at the surface of a standing patient may result in significant dose variations due to variable skin distance, self shielding, irradiated fields overlapping and patient motion. Deviations occur from the prescription dose up to 40% and the surface dose inhomogeneity as much as 90% in body areas such as the perineum and eyelid, are revealed in the literature. To improve this condition, a selection of patients with advanced skin disease and regional extension could be cured by a combination of TSEB and photon beam irradiation. Helical tomotherapy (HT) has advantages in irradiating extended volumes with treatment length of up to 160 cm, continuously in a helical pattern without the need for field junction. Total marrow irradiation (TMI) via HT with low toxicities for bone marrow transplantation of Asia multiple myeloma patients could be feasible . A study of HT for total scalp irradiation has also shown that the employment of directional and complete blocking on the inner structures can effectively force the tangential delivery of the majority of beamlets to the PTV, which can limit the treatment depth. Using HT, an image-guided intensity-modulated radiotherapy, to replace conventional TSI technique to increase dose delivery and decrease toxicities could be a workable and feasible. Here, we applied TSI via HT (HITS) for a woman with T cell lymphoma failure by chemotherapy, topic UV irradiation and local radiotherapy (RT) in MMH to overcome the surface dose inhomogeneity by conventional RT. Additionally, we will compare the advantages and disadvantages between the plan of HT and conventional RT for TSI.
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas
Lymphoma,Non-HodgkinDiffuse Large B Cell Lymphoma1 moreThe purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients...
Diffuse Large B Cell LymphomaPeripheral T Cell LymphomaThe purpose of this study is to evaluate the effectiveness of circulating DNA from peripheral blood for predicting the prognosis and relapse in DLBCL and PTCL patients.
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who...
Crohn's DiseaseUlcerative Colitis (UC)1 moreTo collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with Hepatosplenic T-cell Lymphoma (HSTCL), for the purpose of identifying potential biomarkers and genetic mutations in patients who have developed HSTCL.
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal...
Extranodal NK/T-cell LymphomaThis program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.
Expanded Access to Tipifarnib
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
T-cell LymphomaNK-Cell Lymphoma1 moreThe designed study follows up on the previous one by the international T-cell project (Bellei et al,, 2012) and its purpose is to verify whether a prospective collection of data would permit access to more accurate information permitting a better definition of prognosis and investigation of more adequate treatment strategies for these neoplasms. The analysis of patients distributed in all five macro regions of the country and a comparison among them will provide a real picture of the disease in Brazil, limiting the bias probably found in the previous projects.
Cohort of Peripheral T Cell Lymphoma
LymphomaT-Cell2 moreProspective, observational cohort study of peripheral T cell lymphoma. Purpose is to investigate the complication including febrile neutropenia in the era of pegylated G-CSF prophylaxis.